\n \n \n “. concat(self. i18n. t(‘search. voice. recognition_retry’), “\n
Gan Yavne, Israel –News Direct– Appyea
SleepX, a subsidiary of AppYea (OTC: APYP) that focuses on generating accurate portable follow-up responses to treat sleep apnea and snoring, announces that it has won approval from the Helsinki Committee to begin its planned clinical trial of the SleepX PRO app.
This follows the company’s recent update that it intends to check the SleepX Pro app in a hospital sleep lab. The test is the first step toward an FDA approval application in the medical device category, the first of its kind, sleep apnea screening, to be conducted through synthetic respiratory sleep intelligence (AI) research.
SleepX Pro, which is designed to diagnose sleep apnea with a smartphone alone, does not require physical contact with the subject.
The global sleep tracking products market is expected to generate profits of USD 11,234. 55 million through 2028 and grow at a CAGR of 17. 50% in 2020-2028; Growing considerations about sleep-related disorders to drive market growth, according to Kenneth Research (May 16, 2022).
“Poor sleep is linked to a weakened immune system, core challenges, reduced physical and intellectual performance, temperament challenges, obesity and many other fitness challenges,” said Neil Kline, founder and former CEO of the American Sleep Association and a member of AppYea’s board of directors. . . ” Unfortunately, many other people with sleep-disordered breathing disorders, such as sleep apnea, go undiagnosed and untreated. Our purpose in this unique generation is to raise awareness of the challenge and how other people can live healthier, fuller lives.
“SleepX PRO is a unique, fast and easy-to-use diagnostic tool that will prevent subjects from having to spend nights in sleep labs while saving millions of dollars to healthcare formula and insurance corporations,” said Boris (Bary) Molchadsky, president. and CEO of SleepX and President of AppYea. ” We plan to make our diagnostic solution highly available for other people to get tested easily.
SleepX is an Israeli studies and progression company recently acquired through AppYea. The company had developed an exclusive product to control and treat sleep apnea and snoring. The generation is through several foreign patents and the company plans to start mass production in 2022. The company lately is focusing its activities on the progression and commercialization of its flagship product DreamIT.
Legal notice on forward-looking statements
This press release contains forward-looking statements. Such statements involve hazards and uncertainties that may cause actual effects to differ materially from those presented herein. Nothing contained in this document should be construed as an offer or a solicitation of an offer to buy or sell any securities. Although APYP believes that the expectations reflected in the forward-looking statements and the assumptions on which they are based are reasonable, APYP cannot guarantee that those expectations and assumptions will prove to be correct. Forward-looking statements, which involve assumptions and describe our long-term plans, methods and expectations, are sometimes identified by the use of the words “may”, “will”, “will”, “may just”, “expect” , “anticipate”, “estimate”, “believe”, “intend” or “project” or the negative of those words or other variations of those words or comparable terminology. The reader is cautioned not to place undue reliance on such forward-looking statements, as such statements are subject to uncertainties and uncertainties, including, but not limited to, adverse economic conditions, intense competition, access to new products and competition, and local changes. government regulations, inadequate capital, unforeseen pricing and operating deficits, higher general and administrative expenses, unforeseen losses, currency conditions and inventory prices, inability to conduct research, advancement and marketing, and other express perils. APYP assumes no legal responsibility to publicly update any forward-looking statement. Neither APYP nor SLEEPX is subject to the reporting requirements of the Securities and Exchange Commission under the Securities and Exchange Act of 1934, as amended.
Asaf Porat
1 800-674-3561
info@appyea. com
http://www. appyea. com
See the newsdirect. com edition: https://newsdirect. com/news/sleepx-approved-by-the-helsinki-committee-to-conduct-clinical-trial-with-the-sleepx-pro-smartphone-application- 244530452